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BACKGROUND: Hydroxypyrones represent several classes of molecules known for their high synthetic versatility. This family of
molecules shows several interesting pharmaceutical activities and is considered as a promising source of new antineoplastic
compounds.
METHODS: In the quest to identify new potential anticancer agents, a new maltol (3-hydroxy-2-methyl-4-pyrone)-derived molecule,
named malten (N,N0-bis((3-hydroxy-4-pyron-2-yl)methyl)-N,N0-dimethylethylendiamine), has been synthesised and analysed at both
biological and molecular levels for its antiproliferative activity in eight tumour cell lines.
RESULTS: Malten exposure led to a dose-dependent reduction in cell survival in all the neoplastic models studied. Sublethal
concentrations of malten induce profound cell cycle changes, particularly affecting the S and/or G2-M phases, whereas exposure to
lethal doses causes the induction of programmed cell death. The molecular response to malten was also investigated in JURKAT and
U937 cells. It showed the modulation of genes having key roles in cell cycle progression and apoptosis. Finally, as part of the effort to
clarify the action mechanism, we showed that malten is able to impair DNA electrophoretic mobility and drastically reduce both PCR
amplificability and fragmentation susceptibility of DNA.
CONCLUSION: Taken together, these results show that malten may exert its antiproliferative activity through the induction of complex
DNA structural modifications. This evidence, together with the high synthetic versatility of maltol-derived compounds, makes malten
an interesting molecular scaffold for the future design of new potential anticancer agents.
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Despite increasing advances in modern treatments for tumours,
the survival of many patients affected by cancer remains extremely
poor. The high possibility of relapse, the absence of specific
therapies and resistance to standard chemotherapy represent the
main causes of failure in cancer treatment (Souhami and Tobias,
2005). There is an urgent necessity for research focused on the
identification and description of new antitumour agents.
Hydroxypyrones and their close congeners, hydroxypyridi-
nones, comprise several classes of molecules characterised by
high synthetic versatility. Their affinity for a wide range of metal
ions makes them ideal metal chelators in the formulation of
therapeutic and diagnostic metallopharmaceuticals. These families
of molecules are used, or have good potential, in clinical
applications, such as in the improvement of metal ion balance in
disorders of metal metabolism, the enhancement of tissue uptake
and retention of insulin-enhancing agents, as well as in protection
from heavy metal ion toxicity and attenuation of redox metal
neurotoxicity (Thompson et al, 2006).
Maltol (3-hydroxy-2-methyl-4-pyrone), one of the best known
hydroxypyrones, is a natural compound extensively used for its
flavour and antioxidant properties (Gralla et al, 1969; Bjeldanes
and Chew, 1979) as an additive in food, beverage, tobacco, brewing
and cosmetics. Although its high bioavailability and favourable
toxicity profiles have been known for a long time, maltol was
found to perform interesting antineoplastic activities against
different cancer cellular models. Reactive oxygen species (ROS)
generation and the consequent induction of DNA breaks have been
hypothesised as a possible mechanism responsible for this activity
(Hironishi et al, 1996; Yasumoto et al, 2004; Murakami et al,
2006a,b).
Furthermore, several maltol-derived compounds have been
synthesised and exploited in the formulation of new potential
metal-based antitumour drugs that can interfere with DNA (e.g.,
DNA binding, DNA intercalation and ROS generation), providing
interesting results (Jakupec and Keppler, 2004; Barve et al, 2009;
Kandioller et al, 2009). In the belief that these compounds have
good potential as anticancer agents, we synthesised new maltol-
derived molecules and investigated their biological activity.
In this study, the antineoplastic potential of a selected molecule,
malten (N,N0-bis((3-hydroxy-4-pyron-2-yl)methyl)-N,N0-dimethyl-
ethylendiamine), was evaluated for its ability to decrease the
Received 9 March 2010; revised 6 May 2010; accepted 24 May 2010;
published online 22 June 2010
*Correspondence: Dr M Fanelli; E-mail: mirco.fanelli@uniurb.it
British Journal of Cancer (2010) 103, 239–248
& 2010 Cancer Research UK All rights reserved 0007– 0920/10
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
ssurvival of eight different tumour cell lines. Subsequently, cell
cycle modifications and the induction of programmed cell death
were investigated at both biological and molecular levels to clarify
the biological response to malten exposure. Finally, the malten
action mechanism was investigated in both cellular and cell-free
assays, directing attention to the possible cause of changes in DNA
structure.
MATERIALS AND METHODS
Chemicals and synthesis of malten
All chemicals and compounds used in this study
  maltol,
  N,N 0-dimethylethylendiamine (DMEDA),
  3-hydroxy-2-dimethylaminomethyl-4-pyrone (DMAMP), and
  cisplatin (CDDP)
were of the highest quality, commercially available and purchased
from Sigma-Aldrich (St Louis, MO, USA). The synthesis of
malten (research paper in preparation) was carried out as follows:
a protected maltol derivative was synthesised by silylation and
allylic bromination of commercial maltol. After removal of the
hydroxyl protective group and without purification, the maltol
derivative was combined with N,N0-dimethylethylenediamine.
Malten was then purified by precipitation as perchlorate salt,
obtaining an overall yield of 50%.
Cell cultures, treatments and cell survival estimates
Immortalised promonocytic leukaemia (U937), acute promyelo-
cytic leukaemia (NB4), acute myeloid leukaemia (HL-60), T-cell
leukaemia (JURKAT), glioblastoma multiforme (U-373MG), cervix
carcinoma (HeLa), malignant pleural mesothelioma (H28) and
alveolar rhabdomyosarcoma (RH30) human tumour cell lines
were obtained from American Type Culture Collection (ATCC,
Rochville, MD, USA).
Cellular populations derived from solid tumours were cultured
in DMEM (Cambrex, Walkersville, MD, USA), whereas cells
derived from haematopoietic malignancies were grown in RPMI
1640 (Cambrex, Walkersville, MD, USA). Both culture media were
supplemented with 10% foetal bovine serum, 1% penicillin–
streptomycin and 1% glutamine. All cell lines were grown in a
humidified atmosphere at 371C as previously described (Fanelli
et al, 2008).
Malten was dissolved at 25mM in double-distilled water as stock
solution, stored at  801C and subsequently diluted before use.
Treatments were carried out at the concentrations reported in the
figures and repeated every 24h. Cellular viability was evaluated by
Trypan blue dye exclusion assay 72h after treatment started. The
50% inhibitory concentration (IC50) was calculated for each cell
line as the drug concentration, which resulted in a 50% reduction
of viable cells compared with untreated cells.
Cell cycle analysis and hypodiploid cells estimation
Cell cycle and hypodiploid cells were analysed using the propidium
iodide staining procedure as previously reported (Amatori et al,
2009). Cells were fixed in ice-cold 70% ethanol and stained
using a propidium iodide staining solution (50mgml
 1). Cyto-
fluorimetric acquisitions were carried out with a BD FACScalibur
flow cytometer (BD Biosciences, San Jose, CA, USA) and sample
analysis was carried out with FlowJo 8.6.3 software (Tree Star, Inc.,
Ashland, OR, USA). Cell cycle percentage values were calculated
using a Watson pragmatic model and the significance of changes
was evaluated by a Student t-test (Po0.05).
DNA laddering assay
About 2 10
6 cells were harvested, washed once with ice-cold PBS
and incubated in 2ml of 1  TBS, 0.5% Tween20 and 1mM EDTA
for 30min at 41C. Cells were centrifuged at 1200r.p.m. for 5min
at 41C and incubated with 0.1% SDS solution for 30min at
room temperature, in a final volume of 0.5ml. DNA was purified
using a QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany),
following the manufacturer’s instructions, separated by 2%
agarose gel electrophoresis (AGE) and detected by ethidium
bromide staining.
Quantitative reverse transcriptase(Q-RT)–PCR and
western blotting
RNA isolation, real-time RT–PCR assay and subsequent analysis
were carried out as previously described (Caprodossi et al, 2005).
Amplifications were carried out using a PCR array designed to
simultaneously analyse the expression levels of 37 different genes
in 100-well discs (Corbett Life Science, Sydney, Australia–research
paper in preparation). The following genes, known to have key
roles in cell cycle regulation, were investigated (primer sequences
available on request):
ABL1, ATM, ATR, BAX, BCL2, BIRC5 (survivin), BRCA1, BRCA2,
CCNB1 (cyclin B1), CCNB2 (cyclin B2), CCNE1 (cyclin E1), CDC16,
CDC2, CDC20, CDC34, CDK2, CDK4, CDK6, CDK7, CDK8, CDKN1A
(p21), CDKN1B (p27), CDKN2A (p14-p16), CDKN2B (p15), CDKN3
(KAP), CHEK1, CHEK2, CUL3, E2F4, GADD45A, KNTC1, MCM2,
MKI67 (Ki-67), PCNA, RPA3, TP53, UBE1.
Primers were designed using Primer Express software (PE
Applied Biosystem, Foster City, CA, USA) and PCR assays were
applied in a Rotor-Gene 6000 robocycler (Corbett Life Science,
Sydney, Australia). The expression of different transcripts was
normalised with GAPDH expression levels, and calculated as fold
induction with respect to untreated cells. Filtering of results
was carried out as follows: genes were considered regulated when
their change was greater than ±2.5-fold.
Western blotting analyses were performed as previously
described (Fanelli et al, 2008). Anti-p15 (#4822), anti-p21
(DCS60–#2946), anti-CDK6 (DCS83–#3136) and anti-PCNA
(PC10–#2586) antibodies were purchased from Cell Signalling
Technology (Beverly, MA, USA); anti-p16 (H156–sc759) and anti-
p53 (pDO-1–sc126) antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA); the anti-a tubulin (Clone
DM1A–T9026) antibody was purchased from Sigma Aldrich
(St Louis, MO, USA); and anti-BRCA1 (Ab-1 #OP92) was
purchased from Calbiochem (San Diego, CA, USA).
DNA electrophoretic mobility assay
A volume of 100–500ng of circular pLL3.7 plasmid DNA
(resuspended in 1  TE) was incubated with the compounds
tested in 20mlo f1 0 m M Tris-HCl (pH 7.4) buffer (371C), at the
reported concentrations and time points. After incubation, DNA
was separated by 0.8% AGE and then stained by ethidium bromide.
Ascorbic acid and CuSO4 at equimolar concentrations (50nM) were
used as a control of plasmid linearisation induced by DNA breaks
(Gaetke and Chow, 2003).
Alternatively, linear pLL3.7 plasmid DNA, previously incubated
with malten or CDDP for 2h at 371C under conditions already
described, was partially fragmented through mild sonication
(once 10s at 20W–Labsonic L sonicator–B. Braun Biotech
International, Melsungen, Germany) and separated by AGE.
DNA electrophoretic mobility assay of genomic DNA was
carried out as follows: U937 cells, treated with malten for 8h at
the concentrations reported, were harvested, washed with ice-cold
1  PBS, resuspended in a solution containing 1  PBS, 0.1% SDS,
10mg/ml RNase A and incubated overnight at 41C. Genomic DNA
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staining.
PCR inhibition assay
A volume of 500ng of pLL3.7 plasmid DNA (in 1  TE), incubated
with 4mM malten (2h at 371C) under conditions already described,
was diluted to 0.25pg/ml with double-distilled water and amplified
(2ml) by real-time Q-PCR using the following sets of primers—
characterised by a common reverse primer and able to amplify
the same plasmid region producing amplicons of different length
(121, 301 and 622bp):
pLLF1: 50-AATACCGCGCCACATAGCAG–30,
pLLF2: 50-GTTGTCAGAAGTAAGTTGGCCGC–30,
pLLF3: 50–GCTGCAATGATACCGCGAGAC–30 and
pLLR: 50-GTGCACGAGTGGGTTACATCG–30.
Q-PCR experiments and subsequent analysis were carried out
as previously described (Caprodossi et al, 2005).
RESULTS
Malten synthesis and antiproliferative effects against
tumour cell lines
The new maltol-derived molecule malten, prepared as shown in
Figure 1 (described in Material and Methods), was obtained after
precipitation as a white solid perchlorate salt (L
.2HClO4), light-
and air stable, easy to handle and, more importantly for future
applications, soluble in water.
Different tumour cell lines, comprised of cells derived from both
solid and haematopoietic malignancies, were subjected to 72h
of exposure to malten in dose–response experiments to evaluate
the biological effects. We found that treatments with malten at
concentrations ranging between 5 and 50mM result in a dose-
dependent reduction in cell survival (Figure 2A). Subsequently,
IC50 value was calculated for each cell line showing appreciable
variations (from 4.54±0.66mM to 30.47±6.75mM) and indicating
a certain cell-type specificity of malten activity (Figure 2B).
Interestingly, RH30 was the most sensitive cellular population
suggesting the presence of peculiar molecular features in
alveolar rhabdomyosarcoma that could render this cell line more
susceptible to malten exposure.
Analysis of malten-mediated cell cycle perturbations and
induction of programmed cell death
The biological response to malten was further detailed by
analysing the effects on cell cycle progression. Malten treatment
of 72h, at concentrations of 5, 10 and 25mM, induced cell cycle
perturbations that could be monitored in all the cell lines
considered in this study. The effects were dose dependent and
are characterised by the accumulation of cells mainly in S and/or
G2-M phases (Figure 3; Table 1 and Supplementary Figure S1).
O
O
O
2
Si
CH3 CH3
H3C
+ N
H
N
CH3 TEA
O
O
OH
N
N CH3
CH3
O
O
OH
Malten (2) (1)
THF H
CH3
CH3 CH3
Br
Figure 1 Scheme of malten synthesis. (1) maltol derivative; (2) N,N0-dimethylethylenediamine.
U937 U-373MG
100
0
20
40
60
80
100
0
20
40
60
80
HeLa NB4
80
100
0
20
40
60
80
100
0
20
40
60
C
e
l
l
 
s
u
r
v
i
v
a
l
 
(
%
)
H28 JURKAT
40
60
80
100
0
20
40
60
80
100
0
20
HL-60 RH30
0
20
40
60
80
100
0
20
40
60
80
100
Malten (M)
I
C
5
0
 
(

M
)
30
35
10
15
20
25
0
5
05 0 25 10 5
05 0 25 10 5
05 0 25 10 5
05 0 25 10 5 05 0 25 10 5
05 0 25 10 5
05 0 25 10 5
05 0 25 10 5
U937
NB4
JURKAT
HL-60
U-373MG
HeLa
H28
RH30
Figure 2 Reduction of cell survival induced by malten treatments in eight
different tumour cell lines. Cells were treated for 72h with the reported
concentrations of malten and analysed by Trypan blue dye exclusion assay.
The data are reported as mean (±s.d.) resulting from three independent
experiments. (A) Dose–response experiments. (B) IC50.
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sInteresting differences between the cell lines were also detected.
In particular, JURKAT and RH30 cells showed a robust reduction
of cells in G1 phase concomitantly with an evident G2-M cell cycle
arrest (Figure 3 and Table 1).
Malten-mediated apoptosis was also evaluated, after 72h of
treatment, monitoring an increase of hypodiploid cells (Figure 4A
and Supplementary Figure S2), with differences observed between
the cell lines tested. Activation of the apoptotic programme was
subsequently confirmed by analysing the internucleosomal DNA
fragmentation induced by malten exposure in U937 cells, at
concentrations of 10, 25 and 50mM (Figure 4B).
The biological effects mediated by malten treatments were also
investigated at the molecular level by analysing the expression of a
panel of genes known to regulate cellular proliferation, apoptosis
and cell cycle progression.
JURKAT and U937 cells were chosen as representative model
systems that recapitulate the different biological responses of the
cell lines tested. The results obtained by comparing untreated cells
with those treated with malten at concentrations of 8 and 10mM
(across the IC50 value) show changes in the mRNA level involving
genes having key roles in the control of cell cycle and DNA damage
response (Figure 5A and B). In particular, among cyclin-dependent
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Figure 3 Examples of malten-induced cell cycle perturbation in tumour cells. Cells were exposed for 72h to the reported concentrations of malten
(n.t.¼not treated cells). Cell cycle profiles have been evaluated by flow cytometric analysis of propidium iodide-stained cells (see Supplementary FigureS 1
for the other cell lines tested).
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skinase inhibitors (CDKIs), we found the evident upregulation of
p21 (CDKN1A), p15 (CDKN2B) and p16 (CDKN2A) in both cell
lines and at both malten doses, whereas p27 (CDKN1B) remained
unchanged (Figure 5A and B).
The upregulation of BRCA1 and CUL3 at both doses of malten
was only observed in JURKAT cells (Figure 5A). Subsequently,
genes showing the highest transcriptional modulations were
further investigated at protein level. Western blot analysis
confirmed the increased expression of p21, p16 and p15 in both
cell lines, whereas no changes were monitored for PCNA and
CDK6 proteins as they were already monitored at mRNA level
(Figure 5C).
P53 is known to be functionally activated prevalently by protein
stabilisation, hence its accumulation was monitored. We observed
a slight increase in JURKAT cells after malten treatments and, as
expected (Decker et al, 2003), the complete absence of expression
in U937 cells (Figure 5C). The expression level of BRCA1 protein
was not detected, probably because of the low sensitivity of the
antibody tested.
Evaluation of DNA structural modifications induced by
malten
As already reported, maltol can damage DNA through ROS
production (Murakami et al, 2006a,b). We first tested the
hypothesis that malten could cause DNA breaks by analysing its
effect on circular plasmid DNA by AGE. Dose–response experi-
ments showed that after 16h of malten exposure, there was neither
plasmid linearisation nor evident DNA degradation (Figure 6A).
However, we observed that malten is able to modify the
electrophoretic mobility of plasmid DNA causing the complete
trapping of DNA at the top of the gel at the higher concentrations
tested. This phenomenon is strictly dependent on incubation, as
shown by the normal pattern of migration of plasmid DNA at
the higher malten dose (4mM) when incubation was omitted
(Figure 6A, lane n.i.), indicating that the presence of malten per se
does not disturb the electrophoretic migration of DNA. DNA
complexes with impaired electrophoretic mobility were also found
using shorter exposure times and a malten concentration of
4m M (Figure 6B).
We then investigated malten-induced effects on the genomic
DNA of cancer cells. U937 cells were exposed to different doses of
malten (from 0.1 to 1mM) for a relatively short period of time (8h)
to maximise the effect of the compound and avoid any interference
from the biological response (e.g., internucleosomal cleavage of
DNA related to the apoptotic response). We found that U937 cells
exposed to malten show a concentration-dependent reduction of
electrophoretic mobility of their genomic DNA (Figure 6C).
Having established that the induction of DNA modifications can
also occur in the cellular compartment, we investigated whether
this phenomenon was a peculiar feature of the malten chemical
Table 1 Cell-cycle modifications induced by malten treatments
a
Cell lines lM % G1 % S % G2-M
U937 0 39.3±3.5 51.3±5.5 6.9±0.9
5 36.2±3.4 49.6±4.2 12.3±1.6
b
10 26.3±2.9
b 59.1±5.3 13.7±1.9
b
25
c ———
NB4 0 34.6±5.5 54.4±3.5 9.8±1.5
5 34.1±2.6 52.2±3.3 11.6±2.4
10 29.4±4.0 53.5±4.5 16.4±2.3
b
25
c ———
JURKAT 0 40.8±3.7 34.1±5.3 22.5±2.5
5 28.7±3.5
b 37.1±3.7 30.5±2.9
b
10 19.1±4.6
b 29.7±4.4 47.5±4.8
b
25
c ———
HL-60 0 33.3±4.1 43.5±3.2 19.7±2.9
5 29.3±2.4 48.2±4.4 20.1±2.8
10 26.9±4.1 58.0±2.0
b 14.9±0.4
25 25.5±2.6 59.9±3.2
b 13.8±1.4
U-373MG 0 46.2±2.6 40.2±4.1 12.3±2.8
5 40.8±3.0 43.1±3.6 15.6±3.1
10 36.9±4.7 43.3±2.5 18.9±1.9
b
25 32.9±2.6
b 46.7±4.0 20.8±2.0
b
HeLa 0 59.6±3.3 29.1±2.0 10.1±1.7
5 57.2±1.9 30.6±2.1 10.3±1.4
10 56.4±2.1 28.4±2.1 13.6±2.1
25 44.9±3.5
b 40.0±2.8
b 14.1±1.6
b
H28 0 65.6±6.2 23.5±2.1 9.9±1.2
5 58.7±3.0 28.6±3.7 10.1±1.0
10 55.2±6.1 29.3±4.8 13.2±2.6
25 51.2±2.6
b 26.8±3.1 20.0±1.5
b
RH30 0 34.4±3.2 44.7±5.0 20.0±2.1
5 27.2±1.6
b 38.7±1.8 33.8±1.5
b
10 15.3±2.7
b 38.9±6.5 46.0±3.7
b
25 6.9±2.1
b 40.2±2.0 52.0±3.6
b
aData represent mean values±standard deviation (s.d.) of three independent
experiments.
bStatistically relevant variations respect to untreated controls (Student’s
t-test, Po0.05).
cSamples for which the software was not able to analyze the
cell cycle.
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Figure 4 Malten-mediated induction of programmed cell death.
(A) Percentage of hypodiploid cells induced by malten at the final
concentration of 50mM. Cells were analysed by propidium iodide staining
and flow cytometric analysis; hypodiploidy induction was calculated as the
difference between the percentages of hypodiploid cells in treated and not
treated samples (see Supplementary Figure S2 for cytometric analysis of all
the malten doses tested for each tumour cell line). (B) Apoptosis-related
DNA fragmentation induced by 72h malten exposure in U937 cells at
the final concentration of 10, 25 and 50mM (n.t.¼not treated cells).
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sstructure. To this end, plasmid DNA was exposed to compounds
such as maltol, DMEDA and DMAMP, which represent part of
the malten molecule and CDDP. Intriguingly, we found that the
electrophoretic interferences on plasmid DNA are peculiar to the
malten molecular structure and that CDDP, as expected (Bellon
et al, 1991), causes just a slight retardation in the mobility of the
supercoiled plasmid form (Figure 6D). Moreover, in accordance
with cell-free studies, maltol, DMEDA and DMAMP failed to
induce a biological response in any of the cellular models tested
(data not shown).
Finally, we further investigated the possibility that malten could
molecularly modify the DNA structure by assaying its interference
on DNA amplification. Plasmid DNA was amplified after malten
exposure, by Q-PCR, using three sets of primers sharing the same
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Figure 5 Gene expression modifications induced by malten. JURKAT (A) and U937 (B) cells were subjected to malten treatments at the concentration
of 8mM (grey bars) and 10mM (black bars). Transcript abundance of genes involved in cell cycle regulation, cellular replication and apoptotic response was
assessed by Q-PCR, normalised with GAPDH expression and evaluated as fold induction with respect to untreated cells. (C) Western blot analysis of
malten-treated and untreated (n.t.) JURKAT and U937 total cell lysates.
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sreverse oligonucleotide and able to generate amplicons of different
sizes (121, 301 and 622bp). First, we revealed that incubation with
malten decreases the efficiency of PCR amplification (Figure 6E,
upper panel). It is important that, despite doubling the amplicon
size (121, 301 and 622bp), malten induced an exponential loss
of PCR efficiency ( 7.13-fold,  99.7-fold,  6472-fold; Figure 6E
upper panel—see Discussion).
Taken together, these results strongly support the hypothesis
that malten can induce DNA structural modifications at a high
level of complexity.
DISCUSSION
In this paper, we provide the biological properties of a new
synthetic maltol-derived molecule (malten) and the preliminary
attempt to understand its molecular mechanism of action.
The sensitivity to malten exposure of different tumour cell lines
(derived from haematopoietic and solid tumours) was assayed in
terms of decreased cell survival, programmed cell death induction
and cell cycle perturbation.
Malten was able to drastically reduce the cell survival of all
cell lines tested, showing interesting differences in terms of
responsiveness and suggesting the presence of peculiar molecular
properties that may render some cellular models more susceptible.
High doses of malten activated the apoptotic cellular response,
whereas sublethal treatments induced the accumulation of cells
in both S and/or G2-M phases in almost all cell lines.
However, JURKAT and RH30 cells, two of the most sensitive
cell lines in terms of reduced cell survival, showed a peculiar
accumulation of cells in G2-M phases associated with a strong
decrease of G1 phase, indicating that a possible different ability to
activate cell cycle checkpoints may influence the antiproliferative
effect of malten.
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Figure 6 Effects induced by malten on the DNA structure. (A) Effects on the electrophoretic migration of plasmid DNA (pLL3.7) were investigated by
monitoring the supercoiled (white arrow) and open circular (black arrow) forms abundance, the induction of plasmid linearisation (grey arrow) and the
formation of high-molecular-weight DNA complexes (black bar) after 16h of exposure to different doses of malten. Not treated (n.t.); not incubated (n.i.).
Incubation with ascorbic acid (asc.) in the presence of CuSO4 for 2h as control of plasmid linearisation mediated by ROS. (B) Effects on the electrophoretic
migration of plasmid DNA (pLL3.7) after short times of exposure to 4mM malten. (n.t.), not treated. (C) Genomic DNA modifications induced in U937 cells
exposed for 8h to the reported concentrations (mM) of malten. (D) DNA modifying ability of maltol, DMEDA, DMAMP, malten and CDDP at the
concentration of 4mM. The molecular structure of the compounds tested is schematised at the bottom of the figure. *Retardation in the migration of the
supercoiled plasmid form. (E) PCR inhibition assay. After incubation for 2h in the presence of 4mM malten (upper panel) or 25mM CDDP (lower panel),
circular plasmid DNA (pLL3.7) was amplified by Q-PCR using the sets of primers reported in the figure. DCt was calculated for each set of primers as the
difference between the Ct values of incubated (inc.) and not incubated (n.i.) samples (see Supplementary Figure S3 for treatment of CDDP at the same
concentration of malten). (F) DNA fragmentation assay. After incubation for 2h in the presence of malten or CDDP (both at the concentrations of 4mM),
linearised pLL3.7 plasmid DNA was subjected or not to sonication, and separated by AGE. Linearised plasmid DNA (white arrow); high–molecular-weight
DNA complexes (black arrow).
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levels, support the biological data collected. In particular,
upregulation of the broad-range cyclin-dependent kinase inhi-
bitor (CDKi) p21, found in both JURKAT and U937 cells, is
consistent with the late S and G2-M cell accumulation that we
monitored.
However, the lack of p53 functionality in both cell lines (Cheng
and Haas, 1990; Decker et al, 2003) indicates that the expression
of p21 is induced in a p53-independent manner.
In addition to p21, we also found, in both JURKAT and U937
cells, upregulation of the INK4 family CDK-inhibitors p15 and p16,
which are known to exert their activity during G1–S transition.
An increased expression of CUL3, a member of the cullin-RING
ligase family with ubiquitinating ligase activity, was detected
in JURKAT cells. Considering the crucial role of CUL3 protein
in sustaining caspase-8 activity, and the robust increase of
hypodiploidy observed in JURKAT cells exposed to malten, it
is reasonable to hypothesise that CUL3 upregulation could
contribute to the malten-induced apoptotic response (Be ´ke ´s and
Salvesen, 2009; Lall, 2009).
The biological and molecular aspects monitored strongly indi-
cate that malten exposure may activate a DNA damage response.
The late S and G2-M block is usually associated with compounds
known to form adducts with DNA and actually included in several
therapeutic protocols (e.g., CDDP; Siddik, 2003).
In addition to p16 upregulation, which can also be induced as
a consequence of DNA damage (Robles and Adami, 1998; Shapiro
et al, 1998), malten treatments increased the expression of BRCA1,
which is known to be involved in DNA-damage signalling through
its multifunctional properties as controller of DNA replication,
activator of G2-M checkpoint and as initiator of DNA repair
processes (Huen et al, 2010).
Finally, the slight accumulation of p53 protein in JURKAT cells,
although not functional, can be considered as a further phenom-
enon that supports the induction of a cellular response to DNA
damage.
As a consequence of these observations, the possible DNA
structural alterations induced by malten have been investigated
by cell-free studies. We showed that malten exposure induces
the formation of DNA molecules with strongly impaired electro-
phoretic mobility.
In addition, we showed that treatments of DNA with compounds
that are part of the malten molecule did not show any DNA
modification, indicating that changes in the electrophoretic
properties of DNA are a peculiar feature of the malten molecule.
Interestingly, a similar interference with DNA electrophoretic
mobility has been already described for some DNA alkylating
compounds (Pereira et al, 1998; David-Cordonnier et al, 2002;
Novakova et al, 2009) and has been associated with the formation
of a DNA matrix of high molecular weight, which results from the
interhelical crosslinking of multiple DNA molecules.
In linking cell-free assays with cellular response, it is extremely
important to note that genomic DNA, extracted from malten-
treated U937 cells, shows a dose-dependent reduction in its
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Figure 6 Continued.
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selectrophoretic mobility. This finding suggests that the DNA-
modifying function of malten could also occur in a cellular context.
Moreover, we accumulated further experimental observations
suggesting that malten could trigger complex DNA structural
modifications. The first indication is represented by the ability of
malten to reduce the number of plasmid DNA available for
amplification and thus decrease the efficiency of PCR assay
(Figure 6, upper panel). Surprisingly, when amplicon length
was increased (doubling the amplicon length from 121 to 622bp),
the number of amplifiable sequences decreases exponentially after
incubation with malten (Figure 6E, upper panel).
In our opinion, these results are of great interest, especially
considering the fact that the same assay shows a different
behaviour if applied to plasmids exposed to CDDP. In fact, we
reproduced a CDDP-dependent PCR inhibition similar to that
observed by malten, considering the 121bp amplicon (loss of
amplificability of around seven- to eight-fold; Figure 6E, lower
panel – see Supplementary Figure S3 for treatment of CDDP at
the same concentration of malten). From this, we monitored
a proportional decrease in PCR efficiency as the amplicon was
progressively increased in length: CDDP modifies the single DNA
molecules and is not able to generate intermolecular crosslinking
(different DNA molecules covalently bound); thus, PCR inhibition
is expected to be proportional to the increase in amplicon length.
The observed exponential decreased amplificability of DNA
induced by malten suggests the induction of DNA structural
alterations at a higher level of complexity.
These observations, together with the evidence that malten-
modified plasmid DNA is resistant to fragmentation by both
sonication (Figure 6E) and nuclease digestion (see Supplementary
Figure S4), whereas CDDP-treated DNA is fragmentable, strongly
sustain the idea that malten could induce the formation of
covalently bound DNA structures.
However, at this stage, other activities, such as the induction
of ROS-mediated DNA damage already reported for higher doses
of maltol with respect to those tested in our study (Murakami
et al, 2006a,b), cannot be completely excluded as part of the
malten mechanism of action.
Although more studies will be necessary to completely under-
stand the activity of malten, and the precise mechanism of action,
we believe that this compound can be considered as an interesting
molecular scaffold, worthy of further investigation, with the aim of
developing new potential anticancer agents.
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